• Explore /
  • Poster
  • / AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.

AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.

Abstract Video & Slides Poster

Authors

Naureen Starling

Naureen Starling

The Royal Marsden NHS Foundation Trust, London and Sutton, United Kingdom

Naureen Starling , Katerina Neumann , Bruce Colwell , John H Strickler , Al Bowen Benson III , Jamil Asselah , Yoshito Komatsu , Sara Marques , Ken Edwards , Sean Barton O'Donnell , Neda Stjepanovic , Jenny F. Seligmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05855200

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS240)

DOI

10.1200/JCO.2024.42.3_suppl.TPS240

Abstract #

TPS240

Poster Bd #

P8

Abstract Disclosures

Similar Posters

First Author: Rona Yaeger

First Author: Anne-Claire Hardy-Bessard

First Author: Masahito Kotaka

First Author: Jean Francois Delattre